Stock listing

NASDAQ:ZNTL Zentalis Pharmaceuticals, Inc. Stock

Home listing (NASDAQ) of Zentalis Pharmaceuticals, Inc.

Follow Zentalis Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:ZNTL

$1.36 USD 0.00 (0.0%)

Close on Nov 20, 2026

Past year +4.6% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.33 – $1.50 USDNov 20, 2026
Volume
1.46M sharesNov 20, 2026
Market cap
$133.6M USDAt the close on Nov 20, 2026 · price × 98.27M shares outstanding
52-week range
$1.28 – $6.95 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$3.18M USDMedian day 1.17M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Zentalis Pharmaceuticals, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ZNTL · Home$1.36 USD0.00 (0.0%)1,462,135$1.33$1.50$1.33$1.36Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ZNTL · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.360.000.0%$1.33$1.50$1.331,462,135
$1.36-0.13-8.7%$1.50$1.52$1.361,209,342
$1.49-0.11-6.9%$1.62$1.68$1.481,294,839
$1.60-0.10-5.9%$1.73$1.80$1.581,448,149
$1.70+0.02+1.2%$1.68$1.76$1.631,299,521
$1.68-0.21-11.1%$1.87$1.91$1.641,624,727
$1.89+0.09+5.0%$1.83$1.975$1.811,355,953
$1.80+0.06+3.4%$1.94$1.975$1.7752,560,134
$1.74+0.02+1.2%$1.74$1.81$1.661,273,693
$1.72+0.01+0.6%$1.72$1.825$1.711,294,167
$1.71-0.05-2.8%$1.75$1.82$1.631,641,166
$1.76-0.02-1.1%$1.86$1.89$1.731,115,618
$1.78-0.07-3.8%$1.84$1.96$1.7451,271,091
$1.85-0.11-5.6%$1.95$1.99$1.83889,758
$1.96-0.03-1.5%$1.99$1.99$1.861,332,472
$1.99-0.07-3.4%$2.06$2.11$1.971,446,156
$2.06+0.08+4.0%$2.008$2.095$1.982,204,705
$1.98-0.09-4.3%$2.07$2.118$1.961,721,943
$2.07-0.14-6.3%$2.21$2.215$2.031,044,257
$2.21-0.20-8.3%$2.41$2.41$2.18947,100
$2.41+0.05+2.1%$2.33$2.43$2.29745,800
$2.36-0.03-1.3%$2.36$2.47$2.341,207,000
$2.39+0.09+3.9%$2.31$2.44$2.251,557,100
$2.30+0.17+8.0%$2.33$2.356$2.072,736,400
$2.13-0.11-4.9%$2.25$2.30$2.101,101,800
$2.24-0.08-3.4%$2.27$2.396$2.212,034,800
$2.32-0.08-3.3%$2.44$2.45$2.30865,300
$2.40-0.12-4.8%$2.53$2.54$2.39570,100
$2.52-0.12-4.5%$2.64$2.64$2.51546,100
$2.64+0.13+5.2%$2.56$2.659$2.511612,400
$2.51-0.04-1.6%$2.51$2.535$2.391,272,400
$2.55-0.12-4.5%$2.63$2.68$2.54820,100
$2.67-0.11-4.0%$2.81$2.82$2.65827,600
$2.78+0.26+10.3%$2.69$2.84$2.632,994,700
$2.52-0.085-3.3%$2.64$2.65$2.4951,451,200
$2.605-0.165-6.0%$2.74$2.78$2.581,898,700
$2.77+0.055+2.0%$2.71$2.795$2.6051,011,500
$2.715+0.115+4.4%$2.62$2.81$2.574,779,700
$2.60-0.10-3.7%$2.70$2.70$2.571,273,600
$2.70-0.05-1.8%$2.75$2.77$2.651,067,400
$2.75-0.12-4.2%$2.84$2.89$2.731,173,900
$2.87-0.21-6.8%$3.07$3.09$2.781,451,000
$3.08+0.05+1.7%$3.07$3.14$3.01956,300
$3.03-0.08-2.6%$3.15$3.15$2.995675,300
$3.11+0.03+1.0%$3.07$3.18$2.991,259,700
$3.08-0.02-0.6%$3.18$3.215$3.021,088,500
$3.10-0.03-1.0%$3.23$3.26$3.0351,225,800
$3.13-0.37-10.6%$3.51$3.51$3.121,398,600
$3.50-0.01-0.3%$3.47$3.57$3.44750,400
$3.51-0.08-2.2%$3.63$3.67$3.465787,700
$3.59-0.21-5.5%$3.74$3.765$3.555863,100
$3.80-0.23-5.7%$3.99$4.039$3.79780,400
$4.03+0.04+1.0%$4.00$4.10$3.885519,200
$3.99-0.12-2.9%$4.05$4.185$3.92997,800
$4.11+0.34+9.0%$3.80$4.12$3.731,366,500
$3.77+0.06+1.6%$3.68$3.88$3.68897,800
$3.71-0.05-1.3%$3.68$3.74$3.55863,800
$3.76-0.04-1.1%$3.79$3.79$3.67471,800
$3.80-0.08-2.1%$3.88$3.89$3.72695,400
$3.88-0.01-0.3%$3.87$3.92$3.82430,100
$3.89+0.01+0.3%$3.87$3.93$3.83576,200
$3.88+0.12+3.2%$3.78$3.89$3.78799,148
$3.76-0.065-1.7%$3.84$3.96$3.75988,680
$3.825-0.015-0.4%$3.95$3.95$3.815740,800
$3.84+0.02+0.5%$4.015$4.04$3.781,570,900
Ticker
NASDAQ:ZNTL
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Zentalis Pharmaceuticals, Inc. news

Zentalis Pharmaceuticals, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
24 in the last 12 months · 115 in all · newest Nov 9, 2026 · oldest 2020
Decks
24 decks · latest Nov 9, 2026

Where Zentalis Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ZNTL · Home listing · This pageNASDAQUnited StatesUSD
BOATS:ZNTLBOATSUnited StatesUSD

Valuation

Price/book 0.7× against a median of 2.2×: 2nd lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$62.81M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
0.7×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.2×
Beta vs S&P 500
1.44

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Zentalis Pharmaceuticals, Inc. · NASDAQ:ZNTLUS$133.6M−US$62.81Mn/an/an/a0.7×n/a0.2×1.44
VISEN Pharmaceuticals · HKEX:2561US$140.7MUS$91.39Mn/a29.9×n/a1.4×n/a0.3×n/a
Protara Therapeutics, Inc. · NASDAQ:TARAUS$140.4MUS$15.77Mn/an/an/a1.0×n/a0.0×1.12
Cloudbreak Pharma, Inc. · HKEX:2592US$140.4MUS$82.02Mn/an/an/a2.3×n/a0.0×n/a
Scancell Holdings PLC · LSE:SCLPUS$140.2MUS$155.6Mn/an/an/an/an/an/an/a
Abeona Therapeutics Inc. · NASDAQ:ABEOUS$138.4MUS$15.29Mn/a0.4×n/a1.1×−160.3%0.1×1.00
DX & VX Co., Ltd. · KRX:180400US$134.6MUS$100.6Mn/a5.1×n/a2.2×−99.2%0.1×n/a
Starpharma Holdings Limited · ASX:SPLUS$133.4MUS$126.5Mn/a15.9×n/a14.6×−62.0%0.1×n/a
Sionna Therapeutics, Inc. · NASDAQ:SIONUS$127.8M−US$89.05Mn/an/an/a0.5×n/a0.0×1.51
IntoCell, Inc. · KRX:287840US$127.3MUS$109.4Mn/a45.9×n/a8.7×−295.9%0.0×n/a
Yoda Pharmaceuticals Inc. · TPEX:7829US$127.1MUS$94.39Mn/an/an/a3.9×n/a0.0×n/a
Median of the othersUS$136.5MUS$92.89M15.9×2.2×−129.7%0.0×1.12

Forecasts

8 strong buy · 3 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
7.33 USD · Analysts' mean
EPS, year to Dec 2026
-1.74 · 3 analysts

Team and board

Officers

OfficerRole
Julie EastlandChief Executive Officer and Director
Vincent VultaggioSenior Vice President, Finance & Principal Accounting Officer
James BucherChief Legal Officer and Corporate Secretary
Aron FeingoldVP, Investor Relations & Corporate
Henry GuSenior Vice President, Head of Intellectual Property
Rajesh IsraniExecutive Vice President, Regulatory Affairs & Medical Writing
Sarah KellySenior Vice President, Commercial Strategy
Susan SaffleSenior Vice President, Information Technology
Haibo WangChief Business Officer
Ingmar BrunsChief Medical Officer
Robert DiVastoChief Technical Officer
Wendy ChangChief People Officer

Board

DirectorRole
Scott MyersChairperson
Dave Johnson
Enoch KariukiDirector
Jan SkvarkaDirector
Julie EastlandChief Executive Officer and Director
Luke WalkerDirector
Shannon CampbellDirector

Events

QuarterResultsShare move
Q3 2026Nov 9, 2026 · After close+3.5%
Q2 2026Aug 6, 2026 · After close−15.6%
Q1 2026May 13, 2026−4.4%
Q4 2025Mar 26, 2026 · After close−21.4%
Q3 2025Nov 10, 2025 · After close+6.1%
Q2 2025Aug 6, 2025 · After close+5.1%
Q1 2025May 14, 2025 · After close+5.9%
Q4 2024Feb 25, 2025 · Before open−4.7%
Q3 2024Nov 12, 2024 · After close+5.7%
Q2 2024Aug 9, 2024 · Before open−9.4%
All 20 quarters
QuarterResultsShare move
Q1 2024May 7, 2024 · Before open+5.0%
Q4 2023Feb 27, 2024 · Before open+4.5%
Q3 2023Nov 6, 2023 · Before open−30.2%
Q2 2023Aug 9, 2023 · Before open+0.7%
Q1 2023May 10, 2023 · Before open+6.9%
Q4 2022Mar 1, 2023 · Before open−0.3%
Q3 2022Nov 9, 2022 · Before open−22.0%
Q2 2022Aug 9, 2022 · After close+1.1%
Q1 2022May 5, 2022 · Before open−6.7%
Q4 2021Feb 24, 2022 · Before open+6.7%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck25 slidesNov 9, 2026
Investor Presentation (August 2026)Investor deck29 slidesAugust 2026
Investor Presentation (May 2026)Investor deck29 slidesMay 12, 2026
Investor Presentation (April 2026)Investor deck39 slidesApr 9, 2026
Investor Presentation (January 2026)Investor deck40 slidesJan 9, 2026
Investor Presentation (November 2025)Investor deck37 slidesNov 10, 2025
Investor Presentation (August 2025)Investor deck37 slidesAug 6, 2025
SGO Annual Meeting on Women's Cancer 2025Conference14 slidesMar 17, 2025
Corporate Update (January 2025)Corporate update45 slidesJan 29, 2025
Investor Presentation (June 2024)Investor deck61 slidesJun 3, 2024
All 24 decks
DeckKindSlidesDate
Investor Presentation (April 2024)Investor deck55 slidesApr 9, 2024
Investor Presentation (November 2023)Investor deck55 slidesNov 6, 2023
Investor Presentation (September 2023)Investor deck43 slidesSep 13, 2023
Investor Presentation (August 2023)Investor deck47 slidesAug 9, 2023
Corporate Update (June 2023)Corporate update53 slidesJun 6, 2023
Investor Presentation (June 2023)Investor deck47 slidesJun 6, 2023
Investor Presentation (April 2023)Investor deck55 slidesApr 17, 2023
Investor Presentation (March 2023)Investor deck53 slidesMar 1, 2023
Investor Presentation (January 2023)Investor deck56 slidesJan 9, 2023
Investor Presentation (November 2022)Investor deck56 slidesNov 9, 2022
Investor Presentation (August 2022)Investor deck44 slidesAug 9, 2022
Investor Day (April 2022)Investor day55 slidesApr 8, 2022
Technical Presentation (2022)Technical19 slides2022
Corporate Update (June 2021)Corporate update44 slidesJun 28, 2021

Open Decks

Financings

RaiseDate
Public offering of common stock
Closed: US$92.6M raised · US$3.5 a share · TD Cowen +4
Dealers: TD Cowen (co-lead), Guggenheim Securities (co-lead), Oppenheimer & Co. (co-lead), H.C. Wainwright & Co., Rodman & Renshaw LLC
Use of proceeds: Fund clinical trials, preclinical studies, regulatory filings, manufacturing, companion diagnostic, pre-commercial activities, working capital and general purposes
Aug 18, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$18.00 a share on Apr 2, 2020.

Price
US$18.00 a share
Shares offered
9,180,000 shares of common stock
Offering size
US$165.2 million
Underwriters' option
Up to 1,377,000 more shares
Underwriters
Morgan Stanley, Jefferies, SVB Leerink, Guggenheim Securities · In the order on the cover
Shares delivered
On or about Apr 7, 2020

Steps

StepWhen
Draft sent to the SEC in confidenceJan 8, 2020
Filed publiclyMar 6, 2020
Amended twiceNewest Mar 31, 2020
Shares registered with an exchangeApr 2, 2020
Declared effective by the SECApr 2, 2020
Final prospectus, with the priceApr 6, 2020

Open IPO · From the cover of the final prospectus (424B4) filed Apr 6, 2020

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue067.4M0000014.0K
Cost of revenue739.0K1.29M1.39M1.43M544.0K160.0K111.0K
Gross profit-739.0K67.4M-1.39M-1.43M-544.0K-160.0K-111.0K14.0K
Research and development107.3M167.8M189.6M172.7M175.6M84.9M38.4M18.9M
Selling, general and administrative37.7M87.1M59.4M54.6M40.9M33.9M8.46M4.88M
Operating income-152.8M-191.2M-299.5M-227.3M-216.5M-118.8M-46.8M-23.8M
Depreciation and amortization739.0K1.29M1.39M1.43M544.0K160.0K111.0K51.0K
EBITDA-152.1M-189.9M-298.1M-225.9M-216.0M-118.6M-46.7M-23.7M
Interest expense2.58M110.0M2.23M1.20M0
Income before tax-136.6M-165.7M-292.9M-237.6M-166.4M-118.1M-46.4M-23.4M
Income tax442.0K177.0K-601.0K-469.0K-297.0K444.0K15.0K4.00K
Net income-137.1M-165.8M-292.2M-236.8M-158.7M-117.8M-45.7M-21.1M
Earnings per share, basic-1.91-2.33-4.47-4.48-3.72-4.19-0.77-1.17
Earnings per share, diluted-1.91-2.33-4.47-4.48-3.72-4.19-8.16

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents36.0M33.9M28.0M43.1M59.7M55.0M67.2M25.2M
Short-term investments209.9M318.0M454.9M394.3M280.2M283.6M
Receivables05.00M07.04M4.00K417.0K140.0K917.0K
Inventory-7.04M-4.44M
Current assets253.2M386.1M496.7M451.9M350.8M345.1M68.9M26.7M
Property, plant and equipment2.77M4.70M5.82M7.71M8.15M1.10M501.0K260.0K
Goodwill03.74M3.74M3.74M3.74M3.74M3.74M
Total assets289.0M430.3M551.7M539.3M454.5M365.6M87.5M41.0M
Accounts payable7.21M7.44M14.9M11.2M11.6M8.66M4.29M3.43M
Current liabilities36.6M52.7M69.4M56.6M43.9M28.6M14.9M6.21M
Total debt39.6M42.6M45.8M47.3M45.9M2.00M2.48M
Total liabilities72.8M93.2M114.3M105.3M90.0M32.2M19.1M8.69M
Shareholders' equity216.2M337.2M437.3M433.8M364.0M308.6M-73.3M24.8M
Shares outstanding69.1M71.3M70.8M59.3M45.5M41.0M59.4M18.1M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations-125.2M-170.9M-207.8M-163.8M-154.1M-86.8M-39.1M-24.3M
Capital spending0-221.0K-583.0K-2.55M-6.11M-758.0K-352.0K-227.0K
Free cash flow-125.2M-171.1M-208.4M-166.3M-160.2M-87.6M-39.5M-24.5M
Cash from investing131.6M176.6M-44.5M-114.2M-18.1M-284.8M-352.0K-227.0K
Cash from financing-4.28M108.0K237.3M261.0M178.5M360.4M81.8M9.47M
Share buybacks-9.98M00261.0M-1.15K346.2M81.9M9.47M
Change in cash2.09M5.81M-15.0M-16.9M6.31M-11.2M42.3M-15.0M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 9, 2026Quarterly reportSEC
8-K · Current reportNov 9, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 27, 2026Big-stake noticeSEC
4 · Change in ownershipOct 1, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 19, 2026Big-stake noticeSEC
4 · Change in ownershipAug 19, 2026Insider tradeSEC
8-K · Current reportAug 14, 2026Current reportSEC
424B5 · ProspectusAug 14, 2026Offer documentSEC
Show 200 filings
FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2026Big-stake noticeSEC
424B5 · ProspectusAug 13, 2026Offer documentSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
8-K · Current reportAug 6, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeJul 30, 2026Big-stake noticeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
8-K · Current reportJun 18, 2026Meeting outcomeSEC
4 · Change in ownershipMay 27, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 27, 2026Insider tradeSEC
DEFA14A · Additional proxy materialMay 27, 2026Meeting noticeSEC
8-K · Current reportMay 27, 2026Management or board changeSEC
8-K · Current reportMay 21, 2026Current reportSEC
10-Q · Quarterly reportMay 12, 2026Quarterly reportSEC
8-K · Current reportMay 12, 2026ResultsSEC
8-K · Current reportMay 5, 2026Current reportSEC
DEFA14A · Additional proxy materialApr 30, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 30, 2026Meeting noticeSEC
ARS · Annual report to shareholdersApr 30, 2026Annual reportSEC
8-K · Current reportApr 17, 2026Current reportSEC
8-K · Current reportApr 9, 2026Current reportSEC
10-K · Annual reportMar 26, 2026Annual reportSEC
8-K · Current reportMar 26, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeMar 3, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 10, 2026Insider tradeSEC
4 · Change in ownershipFeb 10, 2026Insider tradeSEC
4 · Change in ownershipFeb 10, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipJan 9, 2026Insider tradeSEC
4 · Change in ownershipJan 9, 2026Insider tradeSEC
4 · Change in ownershipJan 9, 2026Insider tradeSEC
4 · Change in ownershipJan 9, 2026Insider tradeSEC
8-K · Current reportJan 9, 2026Current reportSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
3 · Initial statement of ownershipJan 8, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 5, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJan 2, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeDec 30, 2025Big-stake noticeSEC
4 · Change in ownershipDec 15, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedDec 15, 2025Big-stake noticeSEC
8-K · Current reportDec 15, 2025Management or board changeSEC
SCHEDULE 13G · Big-stake noticeNov 12, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 10, 2025Quarterly reportSEC
8-K · Current reportNov 10, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 14, 2025Big-stake noticeSEC
4 · Change in ownershipOct 1, 2025Insider tradeSEC
3 · Initial statement of ownershipSep 22, 2025Insider tradeSEC
8-K · Current reportAug 26, 2025Management or board changeSEC
10-Q · Quarterly reportAug 6, 2025Quarterly reportSEC
8-K · Current reportAug 6, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 16, 2025Big-stake noticeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
8-K · Current reportJun 18, 2025Meeting outcomeSEC
8-K · Current reportJun 2, 2025Current reportSEC
DEFA14A · Additional proxy materialMay 23, 2025Meeting noticeSEC
8-K · Current reportMay 20, 2025Current reportSEC
S-8 · Registration statement for employee plansMay 14, 2025Offer documentSEC
10-Q · Quarterly reportMay 14, 2025Quarterly reportSEC
8-K · Current reportMay 14, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 13, 2025Big-stake noticeSEC
4 · Change in ownershipApr 30, 2025Insider tradeSEC
DEFA14A · Additional proxy materialApr 30, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 30, 2025Meeting noticeSEC
ARS · Annual report to shareholdersApr 30, 2025Annual reportSEC
8-K · Current reportApr 28, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveApr 7, 2025Other filingsSEC
CORRESP · Letter to the SECApr 2, 2025Other filingsSEC
UPLOAD · Letter from the SECApr 1, 2025Other filingsSEC
8-K · Current reportMar 26, 2025ResultsSEC
S-3 · Registration statementMar 26, 2025Offer documentSEC
10-K · Annual reportMar 26, 2025Annual reportSEC
8-K · Current reportMar 17, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 12, 2025Insider tradeSEC
144 · Notice of proposed saleFeb 11, 2025Other filingsSEC
4 · Change in ownershipFeb 5, 2025Insider tradeSEC
4 · Change in ownershipFeb 5, 2025Insider tradeSEC
4 · Change in ownershipFeb 5, 2025Insider tradeSEC
4 · Change in ownershipFeb 5, 2025Insider tradeSEC
4 · Change in ownershipFeb 5, 2025Insider tradeSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeFeb 4, 2025Big-stake noticeSEC
144 · Notice of proposed saleFeb 3, 2025Other filingsSEC
144 · Notice of proposed saleFeb 3, 2025Other filingsSEC
144 · Notice of proposed saleFeb 3, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 31, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 31, 2025Big-stake noticeSEC
8-K · Current reportJan 29, 2025Current reportSEC
8-K · Current reportJan 28, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 22, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 8, 2025Big-stake noticeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
8-K/A · Current report, amendedDec 19, 2024Management or board changeSEC
SCHEDULE 13G · Big-stake noticeDec 10, 2024Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedDec 6, 2024Big-stake noticeSEC
4 · Change in ownershipDec 3, 2024Insider tradeSEC
4 · Change in ownershipDec 3, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
4 · Change in ownershipNov 13, 2024Insider tradeSEC
3 · Initial statement of ownershipNov 13, 2024Insider tradeSEC
3 · Initial statement of ownershipNov 13, 2024Insider tradeSEC
3 · Initial statement of ownershipNov 13, 2024Insider tradeSEC
8-K · Current reportNov 13, 2024Management or board changeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
SC 13G/A · Big-stake notice, amendedNov 6, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 4, 2024Big-stake noticeSEC
144 · Notice of proposed saleOct 31, 2024Other filingsSEC
SC 13G/A · Big-stake notice, amendedOct 18, 2024Big-stake noticeSEC
UPLOAD · Letter from the SECOct 17, 2024Other filingsSEC
CORRESP · Letter to the SECOct 10, 2024Other filingsSEC
SC 13G/A · Big-stake notice, amendedOct 7, 2024Big-stake noticeSEC
4 · Change in ownershipOct 4, 2024Insider tradeSEC
8-K · Current reportSep 16, 2024Current reportSEC
UPLOAD · Letter from the SECSep 12, 2024Other filingsSEC
10-Q · Quarterly reportAug 9, 2024Quarterly reportSEC
8-K · Current reportAug 9, 2024ResultsSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
8-K · Current reportJun 21, 2024Meeting outcomeSEC
8-K · Current reportJun 3, 2024Current reportSEC
144 · Notice of proposed saleMay 31, 2024Other filingsSEC
4 · Change in ownershipMay 31, 2024Insider tradeSEC
4 · Change in ownershipMay 29, 2024Insider tradeSEC
3 · Initial statement of ownershipMay 29, 2024Insider tradeSEC
DEFA14A · Additional proxy materialMay 29, 2024Meeting noticeSEC
8-K · Current reportMay 29, 2024Management or board changeSEC
144 · Notice of proposed saleMay 9, 2024Other filingsSEC
4 · Change in ownershipMay 9, 2024Insider tradeSEC
10-Q · Quarterly reportMay 7, 2024Quarterly reportSEC
8-K · Current reportMay 7, 2024ResultsSEC
DEFA14A · Additional proxy materialApr 29, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2024Meeting noticeSEC
ARS · Annual report to shareholdersApr 29, 2024Annual reportSEC
3 · Initial statement of ownershipApr 11, 2024Insider tradeSEC
8-K · Current reportApr 11, 2024Management or board changeSEC
8-K · Current reportApr 9, 2024Current reportSEC
S-8 · Registration statement for employee plansFeb 29, 2024Offer documentSEC
S-3ASR · Registration statementFeb 29, 2024Offer documentSEC
10-K · Annual reportFeb 27, 2024Annual reportSEC
8-K · Current reportFeb 27, 2024ResultsSEC
8-K · Current reportFeb 15, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2024Big-stake noticeSEC
144 · Notice of proposed saleFeb 12, 2024Other filingsSEC
144 · Notice of proposed saleFeb 12, 2024Other filingsSEC
144 · Notice of proposed saleFeb 12, 2024Other filingsSEC
4 · Change in ownershipFeb 12, 2024Insider tradeSEC
4 · Change in ownershipFeb 12, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2024Big-stake noticeSEC
4 · Change in ownershipFeb 5, 2024Insider tradeSEC
4 · Change in ownershipFeb 5, 2024Insider tradeSEC
4 · Change in ownershipFeb 5, 2024Insider tradeSEC
4 · Change in ownershipFeb 5, 2024Insider tradeSEC
4 · Change in ownershipFeb 5, 2024Insider tradeSEC
4 · Change in ownershipFeb 5, 2024Insider tradeSEC
144 · Notice of proposed saleFeb 2, 2024Other filingsSEC
144 · Notice of proposed saleFeb 2, 2024Other filingsSEC
144 · Notice of proposed saleFeb 2, 2024Other filingsSEC
144 · Notice of proposed saleFeb 2, 2024Other filingsSEC
144 · Notice of proposed saleFeb 2, 2024Other filingsSEC
144 · Notice of proposed saleFeb 2, 2024Other filingsSEC
SC 13G/A · Big-stake notice, amendedJan 29, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedJan 25, 2024Big-stake noticeSEC
8-K · Current reportJan 25, 2024Management or board changeSEC
8-K · Current reportJan 8, 2024Current reportSEC
4 · Change in ownershipJan 3, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 3, 2024Insider tradeSEC
4 · Change in ownershipDec 21, 2023Insider tradeSEC
SC 13G/A · Big-stake notice, amendedDec 11, 2023Big-stake noticeSEC
SC 13G · Big-stake noticeNov 17, 2023Big-stake noticeSEC
4 · Change in ownershipNov 13, 2023Insider tradeSEC
4 · Change in ownershipNov 13, 2023Insider tradeSEC
10-Q · Quarterly reportNov 6, 2023Quarterly reportSEC
8-K · Current reportNov 6, 2023ResultsSEC
SC 13G · Big-stake noticeOct 10, 2023Big-stake noticeSEC

This page holds 200 of 550 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Zentalis Pharmaceuticals, Inc.’s releases · as of Nov 4, 2026

Common shares
98,265,863
Fully diluted
98,265,863

Fully diluted

LineSharesAs of
Common shares98,265,863Nov 4, 2026

Share count over time

CountShares
Nov 4, 202698,265,863

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Squadron Capital Management LLC6.83M6.9%US$18.9MSep 30, 2026
Vanguard5.2M5.3%US$14.4MSep 30, 2026
Citadel4.49M4.6%US$12.4MSep 30, 2026
5AM Venture Management, LLC3.95M4.0%US$10.9MSep 30, 2026
BlackRock3.91M4.0%US$10.8MSep 30, 2026
ADAR1 Capital Management, LLC3.76M3.8%US$10.4MSep 30, 2026
NEA Management Company, LLC3.57M3.6%US$9.89MSep 30, 2026
Acadian Asset Management LLC3.06M3.1%US$8.46MSep 30, 2026
Two Sigma2.8M2.9%US$7.76MSep 30, 2026
Patient Square Capital LP2.01M2.0%US$5.56MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Seven Fleet Capital Management LP1.5M1.5%US$4.17MSep 30, 2026
Renaissance Technologies1.5M1.5%US$4.15MSep 30, 2026
Opaleye Management Inc.1.41M1.4%US$3.91MSep 30, 2026
Decheng Capital LLC1.32M1.3%US$3.67MSep 30, 2026
Orbimed Advisors LLC1.32M1.3%US$3.64MSep 30, 2026
Geode Capital1.29M1.3%US$3.56MSep 30, 2026
Qube Research & Technologies Ltd1.14M1.2%US$3.14MSep 30, 2026
State Street1.11M1.1%US$3.08MSep 30, 2026
Bank of America1.1M1.1%US$3.06MSep 30, 2026
Ishara Investments LP1.08M1.1%US$2.99MSep 30, 2026
Boxer Capital Management, LLC1.01M1.0%US$2.81MSep 30, 2026
Primecap Management Co957K0.97%US$2.65MSep 30, 2026
Pfizer Inc954K0.97%US$2.58MSep 30, 2026
JPMorgan951K0.97%US$2.58MSep 30, 2026
Ameriprise770K0.78%US$2.13MSep 30, 2026
Soleus Capital Management, L.P.706K0.72%US$1.96MSep 30, 2026
Dimensional706K0.72%US$1.96MSep 30, 2026
Fidelity678K0.69%US$1.88MSep 30, 2026
Connor, Clark & Lunn Investment Management Ltd.665K0.68%US$1.84MSep 30, 2026
Millennium478K0.49%US$1.32MSep 30, 2026
AQR Capital Management LLC447K0.45%US$1.24MSep 30, 2026
Marshall Wace, LLP427K0.43%US$1.18MSep 30, 2026
Gsa Capital Partners LLP410K0.42%US$1.14MSep 30, 2026
Northern Trust403K0.41%US$1.12MSep 30, 2026
Heights Capital Management, Inc350K0.36%US$970KSep 30, 2026
Creative Planning307K0.31%US$849KSep 30, 2026
D. E. Shaw & Co., Inc.270K0.27%US$747KSep 30, 2026
Squarepoint Ops LLC255K0.26%US$706KSep 30, 2026
Stonepine Capital Management, LLC255K0.26%US$706KSep 30, 2026
Susquehanna243K0.25%US$673KSep 30, 2026
Federated Hermes, Inc.238K0.24%US$660KSep 30, 2026
XTX Topco Ltd220K0.22%US$610KSep 30, 2026
UBS205K0.21%US$569KSep 30, 2026
Morgan Stanley204K0.21%US$565KSep 30, 2026
Goldman Sachs183K0.19%US$507KSep 30, 2026
Horizon Investments, LLC172K0.18%US$478KSep 30, 2026
Schwab172K0.17%US$476KSep 30, 2026
Invesco157K0.16%US$435KSep 30, 2026
American Century150K0.15%US$416KSep 30, 2026
Sei Investments Co147K0.15%US$408KSep 30, 2026

This page holds 50 of 123 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund2.19M2.2%US$10.6MJun 30, 2026
iShares Russell 2000 ETF1.24M1.3%US$6.01MJun 30, 2026
PRIMECAP Odyssey Aggressive Growth Fund676K0.69%US$3.21MJul 31, 2026
Vanguard Extended Market Index Fund576K0.59%US$2.79MJun 30, 2026
Fidelity Small Cap Index Fund546K0.56%US$2.59MJul 31, 2026
iShares Russell 2000 Value ETF454K0.46%US$2.2MJun 30, 2026
Vanguard Strategic Small-Cap Equity Fund320K0.33%US$1.55MJun 30, 2026
Fidelity Enhanced Small Cap Core ETF264K0.27%US$1.28MJun 30, 2026
Fidelity Extended Market Index Fund264K0.27%US$1.06MMay 31, 2026
iShares Micro-Cap ETF165K0.17%US$802KJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Dimensional U.S. Small Cap ETF154K0.16%US$732KJul 31, 2026
Vanguard Health Care Index Fund151K0.15%US$602KMay 31, 2026
Schwab Small-Cap Index Fund122K0.12%US$577KJul 31, 2026
Invesco RAFI US 1500 Small-Mid ETF114K0.12%US$539KJul 31, 2026
Fidelity Total Market Index Fund99,5890.10%US$398KMay 31, 2026
Master Small Cap Index Series93,5200.10%US$454KJun 30, 2026
Federated Hermes MDT Small Cap Core ETF79,3620.08%US$317KMay 31, 2026
Avantis U.S. Small Cap Equity ETF78,1500.08%US$313KMay 31, 2026
Fidelity Series Total Market Index Fund77,3300.08%US$309KMay 31, 2026
Ultra-Small Company Market Fund77,3000.08%US$375KJun 30, 2026
U.S. Micro Cap Portfolio76,7410.08%US$364KJul 31, 2026
Fidelity Small Cap Value Index Fund70,0290.07%US$340KJun 30, 2026
Nuveen Small Cap Blend Index Fund66,6740.07%US$316KJul 31, 2026
U.S. Small Cap Portfolio60,6030.06%US$287KJul 31, 2026
EQ/2000 Managed Volatility Portfolio54,1500.06%US$263KJun 30, 2026
Schwab Total Stock Market Index Fund50,0000.05%US$237KJul 31, 2026
Goldman Sachs Absolute Return Tracker Fund47,9050.05%US$232KJun 30, 2026
Fidelity Nasdaq Composite Index Fund46,1380.05%US$185KMay 31, 2026
VIP Disciplined Small Cap Portfolio42,7990.04%US$208KJun 30, 2026
Vanguard Institutional Total Stock Market Index Fund38,0410.04%US$184KJun 30, 2026
LVIP State Street Small-Cap Index Fund37,5000.04%US$182KJun 30, 2026
Vanguard Balanced Index Fund34,4830.04%US$167KJun 30, 2026
Small Cap Index Fund26,0360.03%US$126KJun 30, 2026
U.S. Small Cap Equity Fund25,3960.03%US$120KJul 31, 2026
U.S. Vector Equity Portfolio25,1360.03%US$119KJul 31, 2026
Global X Russell 2000 ETF23,8830.02%US$113KJul 31, 2026
State Street Small/Mid Cap Equity Index Portfolio18,9000.02%US$91,665Jun 30, 2026
MetLife Russell 2000 Index Portfolio17,0640.02%US$82,760Jun 30, 2026
Blackstone Alternative Multi-Strategy Fund15,6000.02%US$75,660Jun 30, 2026
Small-Cap Index Portfolio14,3640.01%US$69,665Jun 30, 2026
1290 VT Micro Cap Portfolio11,2440.01%US$54,533Jun 30, 2026
NVIT Small Cap Index Fund11,2410.01%US$54,519Jun 30, 2026
ATM Small Cap Managed Volatility Portfolio11,1960.01%US$54,301Jun 30, 2026
iShares Russell Small/Mid-Cap Index Fund10,8840.01%US$51,590Jul 31, 2026
Small Cap Index Trust10,6950.01%US$51,871Jun 30, 2026
Dimensional US Core Equity Market ETF10,2520.01%US$48,594Jul 31, 2026
Dimensional US Core Equity 1 ETF10,2340.01%US$48,509Jul 31, 2026
JNL/DFA U.S. Small Cap Fund10,0600.01%US$48,791Jun 30, 2026
Dimensional U.S. Core Equity 2 ETF9,284<0.01%US$44,006Jul 31, 2026
EQ/Small Company Index Portfolio8,550<0.01%US$41,468Jun 30, 2026

This page holds 50 of 91 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Walters William Thurman
10% owner
Buy4,335,000USD 3.50US$15.2MAug 14, 2026

Big stakes

StakeStakeSharesDateFiling
WALTERS GROUP18.80%17.8MAug 14, 2026Schedule 13G
Squadron Capital Management LLC7.30%6.93MSep 30, 2026Schedule 13G
Kush Parmar5.30%5.16MSep 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
David E Goel
Other companies: Alumis Inc. (Director · Jun 27, 2024 – May 21, 2025 · Past); Acelyrin, Inc. (Director · May 4, 2023 – May 21, 2025 · Past); Adaptive Biotechnologies Corporation (Director · Jun 26, 2019 – Feb 15, 2021 · Past); Popular, Inc. (Director · Feb 12, 2012 – May 8, 2018 · Past)
Director · Apr 3, 2020 – Apr 3, 2020 · Past
Julia Marie Eastland
Other companies: Lantheus Holdings, Inc. (Director · Since at least Sep 3, 2024); CalciMedica, Inc. (Director · Jun 2, 2021 – Mar 23, 2023 · Past); Dynavax Technologies Corporation (Director · May 28, 2021 – May 23, 2024 · Past); Harpoon Therapeutics Inc (President and CEO, Director · May 4, 2021 – Mar 11, 2024 · Past)
CEO & President, Director · Since at least Nov 13, 2024
Melissa Epperly
Other companies: Roivant Sciences Ltd. (Director · Since at least Jun 29, 2022); Nautilus Biotechnology, Inc. (Director · Since at least Jun 9, 2021); Kinnate Biopharma Inc (Director · Dec 2, 2020 – Apr 3, 2024 · Past)
Chief Financial Officer · Apr 3, 2020 – Feb 12, 2024 · Past
David Johnson
Other companies: Aura Biosciences, Inc. (Director · Since at least May 4, 2026); Dynavax Technologies Corporation (Vice President · Jun 2, 2019 – Mar 13, 2020 · Past)
Director · Since at least Jun 16, 2026
James B. Bucher
Other companies: Harpoon Therapeutics Inc (Chief Legal Officer · Dec 21, 2023 – Mar 11, 2024 · Past); Climb Bio, Inc. (EVP and General Counsel · Oct 31, 2022 – Oct 31, 2022 · Past)
Chief Legal Officer and Corporate Secretary · Since at least Aug 26, 2025
Jan Skvarka
Other companies: Monte Rosa Therapeutics, Inc. (Executive Chairman, DEM Biopharma · Since at least Mar 23, 2023); Trillium Therapeutics Inc (President and CEO, Director · Jan 1, 2021 – Nov 17, 2021 · Past)
Director · Since at least Sep 9, 2022
Kimberly Blackwell
Other companies: Century Therapeutics, Inc. (Director · Since at least Jun 17, 2021); Monte Rosa Therapeutics, Inc. (Chief Development Officer, Nucleus RadioPharma · Since at least Apr 12, 2021)
Chief Executive Officer, Director · Jul 1, 2020 – Feb 1, 2024 · Past
Luke Walker
Other companies: Context Therapeutics Inc. (Director · Since at least Sep 4, 2024); Harpoon Therapeutics Inc (Chief Medical Officer · Oct 3, 2022 – Mar 11, 2024 · Past)
Director · Since at least May 24, 2024
Cam Gallagher
Other companies: Opus Genetics, Inc. (Director · Since at least Jun 11, 2024)
President, Interim CFO, Director · Feb 1, 2024 – May 31, 2024 · Past
Enoch Kariuki
Other companies: Imago Biosciences Inc (Director · Jul 15, 2021 – Jan 11, 2023 · Past)
Director · Since at least Feb 9, 2021
All 26 people
PersonSeat
Julie Eastland
Other companies: Lantheus Holdings, Inc. (Director · Since at least Feb 26, 2025)
Chief Executive Officer and Director · Since at least Nov 13, 2024
Alexis PintoChief Legal Officer · Aug 31, 2020 – Feb 10, 2022 · Past
Aron FeingoldVP, Investor Relations & Corporate · Since at least Oct 1, 2026
Dave JohnsonDirector · Since at least Nov 13, 2024
Haibo WangChief Business Officer · Since at least Apr 28, 2025
Henry GuSenior Vice President, Head of Intellectual Property · Since at least Nov 4, 2026
Ingmar BrunsChief Medical Officer · Since at least Nov 13, 2024
Kevin D BunkerChief Scientific Officer · Apr 3, 2020 – Dec 20, 2023 · Past
Rajesh IsraniExecutive Vice President, Regulatory Affairs & Medical Writing · Since at least Nov 4, 2026
Robert DiVastoChief Technical Officer · Since at least Nov 4, 2026
Sarah KellySenior Vice President, Commercial Strategy · Since at least May 27, 2026
Scott MyersChairperson · Since at least Nov 13, 2024
Shannon CampbellDirector · Since at least May 26, 2026
Susan SaffleSenior Vice President, Information Technology · Since at least Nov 4, 2026
Vincent VultaggioSenior Vice President, Finance & Principal Accounting Officer · Since at least Apr 5, 2024
Wendy ChangChief People Officer · Since at least Dec 12, 2024

Open People

Log in to ask 6ix AI your own questions about Zentalis Pharmaceuticals, Inc.